Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LTB4R | Q15722 | 3/20 | 0.50 |
| ▸ | LTB4R2 | Q9NPC1 | 3/20 | 0.50 |
| ▸ | USP2 | O75604 | 1/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.44 |
| ▸ | ABCB1 | P08183 | 2/20 | 0.44 |
| ▸ | DRD2 | P14416 | 1/20 | 0.44 |
| ▸ | DRD3 | P35462 | 1/20 | 0.44 |
| ▸ | MTNR1A | P48039 | 2/20 | 0.42 |
| ▸ | PTGS2 | P35354 | 3/20 | 0.41 |
| ▸ | AKR1C3 | P42330 | 3/20 | 0.41 |
| ▸ | AKR1C2 | P52895 | 3/20 | 0.41 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.41 |
| ▸ | CDC42 | P60953 | 1/20 | 0.41 |
| ▸ | RAC1 | P63000 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5788067 | 0.84 | PPARG (0.51) | LTB4RLTB4R2TSHRPPARGPPARD | |
| SCHEMBL17431399 | 0.83 | LTB4R (0.40) | LTB4RLTB4R2CYP3A4 | |
| SCHEMBL205688 | 0.83 | LTB4R (0.40) | LTB4RLTB4R2CYP3A4 | |
| SCHEMBL204322 | 0.83 | LTB4R (0.40) | LTB4RLTB4R2CYP3A4 | |
| SCHEMBL1707953 | 0.82 | LTB4R (0.39) | LTB4RLTB4R2PTGS2PTGS1PPARG | |
| SCHEMBL3502661 | 0.82 | LTB4R (0.39) | LTB4RLTB4R2PTGS2PTGS1PPARG | |
| SCHEMBL15211507 | 0.79 | FFAR1 (0.39) | LTB4RLTB4R2PPARGPPARDFFAR1 | |
| SCHEMBL15211639 | 0.78 | NR4A2 (0.48) | PPARGPPARDFFAR1 | |
| SCHEMBL17431445 | 0.78 | FFAR1 (0.43) | PPARGPPARDFFAR1 | |
| SCHEMBL2835608 | 0.77 | CYP3A4 (0.48) | LTB4RLTB4R2USP2CYP3A4MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2431367-A2 | Fused cyclic compounds as GPR40 receptor modulators | Takeda Pharmaceutical Company Limited (JP) | 2012-03-21 | — | — | EP | disclosed |
| US-20120046338-A1 | FUSED CYCLIC COMPOUNDS | YASUMA TSUNEO (JP) | 2012-02-23 | — | — | US | disclosed |
| EP-2041123-B1 | FUSED CYCLIC COMPOUNDS | TAKEDA PHARMACEUTICAL (JP) | 2012-02-01 | — | — | EP | disclosed |
| US-8088821-B2 | Fused cyclic compounds | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-01-03 | — | — | US | disclosed |
| US-7732626-B2 | Fused cyclic compounds | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-06-08 | — | — | US | disclosed |
| US-20100004312-A1 | FUSED CYCLIC COMPOUNDS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-01-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100004312-A1 | FUSED CYCLIC COMPOUNDS | GPR119, GLP1R, GPR65 | LTB4R 386/4885LTB4R2 429/4885USP2 4732/4885 |
| US-20120046338-A1 | FUSED CYCLIC COMPOUNDS | GPR119, GLP1R, GPR65 | LTB4R 386/4885LTB4R2 429/4885USP2 4732/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.